(Q34112882)

31 July 2017

title

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer (English)

1 reference

31 July 2017

1 reference

8

Carsten Bokemeyer

1 reference

31 July 2017

Gabriela B Iwanski

1

1 reference

31 July 2017

Dhong H Lee

2

1 reference

31 July 2017

Shlomit En-Gal

3

1 reference

31 July 2017

Ngan B Doan

4

1 reference

31 July 2017

Brandon Castor

5

1 reference

31 July 2017

Marco Vogt

6

1 reference

31 July 2017

Melvin Toh

7

1 reference

31 July 2017

Jonathan W Said

9

1 reference

31 July 2017

Nils H Thoennissen

10

1 reference

31 July 2017

H Phillip Koeffler

11

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

British Journal of Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

160

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

998-1007

1 reference

Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Novel advances in pancreatic cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Pancreatic cancer: from molecular pathogenesis to targeted therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

5 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

PEG10 is a c-MYC target gene in cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Cucurbitacins and cucurbitane glycosides: structures and biological activities

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Myc and Max associate in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

Oncogenic activity of the c-Myc protein requires dimerization with Max.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2010.00741.X

Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2010.00741.X

Analysis of genomic targets reveals complex functions of MYC.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2010.00741.X

Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936004

c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance

28 October 2018

1 reference

12 December 2020

Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer

1 reference

12 December 2020

The CFU-C assay in patients with neutropenia and, in particular, drug associated neutropenia

1 reference

12 December 2020

Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides

1 reference

12 December 2020

Drug delivery and targeting

1 reference

12 December 2020

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma

1 reference

12 December 2020

10.1111/J.1476-5381.2010.00741.X

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference